(NewsDirect)
By Julian Richard, Benzinga
BioRestorativeTherapies Inc (NASDAQ: BRTX) is expanding its ThermoStem®intellectual property portfolio for treatments targeting obesity,diabetes and other indications related to metabolic syndrome withanother patent notice of allowance from the United States PatentOffice, adding to its already 19 issued patents under the ThermoStem®patent family. BioRestorative’s ThermoStem® program is a novelcell-based therapy program using cells that have metabolic activity,that once transplanted may be able to regulate the bodies metabolichomeostasis (balance) and potentially induce weight loss and a bettermetabolic state.
Metabolicsyndrome is a cluster of conditions, such as obesity oftentimes resulting in elevated cholesterol (fat) and glucose levels inthe blood, these conditions increase the risk of developing type 2diabetes, heart disease and stroke.
Pioneeringresearch conducted by Biorestorative Therapies demonstratedthat brown tissue burns rather than stores energy. This work waspublished in Stemcells and was performed in a collaboration with the Universityof Utah. Increased levels of brown tissue support weight loss byincreasing metabolism and reducing glucose and cholesterol in theblood. Thus, increasing brown fat levels and activity may be apowerful way to treat metabolic syndrome's significant mortalityand morbidity.
The ThermoStem® program is unique in that it pioneers the useof cell-based therapy to treat a global unmet medical need.
The obesity and metabolic syndromemanagement space is the subject of intenseclinical development and interest in the medical community.ThermoStem® will provide physicians with a therapeutic alternative todrugs with a different mechanism of action currently on the market.with Altimmune (NASDAQ: ALT), Eli Lilly Co (NYSE: LLY) and Pfizer Inc (NYSE: PFE) looking to emulate the successof Semaglutide, marketed by Novo Nordisk A/S (NYSE: NVO) for the treatment of obesity and type 2 diabetes.Semaglutide was FDA-approvedin 2021 for “chronic weight management” and was the firstdrug approved for this indication since 2014. Because ThermoStem® isa biologic rather than a synthetic drug, it might be a saferalternative to drugs currently under development that havedemonstrated safety issues, such as Altimmunes (NASDAQ: ALT) weightloss drug that demonstrated gastrointestinal side effects whenused.
Obesity: A Global Epidemic
Type 1 and type 2 diabetes are two distinctforms of the same disease. Type 1 is an autoimmune disease, whereastype 2 is linked to lifestyle factors such as poor diet and lack ofexercise resulting in obesity.
Type 2 diabetes is caused by excess weight, poordiet and lack of exercise, leading to too much glucose (sugar) in thebloodstream. Cells in the body cannot respond as they would normallyby removing glucose from the blood, a condition called insulinresistance . Type 2 diabetes can often be managed through dietand lifestyle changes such as eating a balanced diet, exercisingregularly and maintaining a healthy weight. However, some people withtype 2 diabetes may also need medication or insulin injections tomanage their condition. Regardless of the type of diabetes, increasedblood sugar can cause diseases ofthe heart, eyes and kidneys and may result in infection and amputationof the feet .
The health economic burden of obesity and type 2 diabetes isprofound. According to the Centers for DiseaseControl and Prevention (CDC), over 37 million Americans havediabetes (about 1 in 10), with up to 95% having type 2 diabetes. Type2 diabetes has historically been considered a disease of adults;however, given the current obesity epidemic, it is becoming morecommon in children, adolescents and younger adults. By 2030, overone billion individuals will be obese, with 1 in 7 men and 1in 5 women living with the condition. The World HealthOrganization has designated obesity as a globalepidemic.
Thetotal annual cost of diabetes in the United States exceeds $327billion. This includes direct medical costs, such ashospitalizations and medications, and indirect costs, from lostproductivity due to illness or premature death.
The burden of obesityand type 2 diabetes is not limited to economic factors alone. Theimpact of these conditions on the quality of life for patients andcarers can be immense. People living with obesity and diabetes are atgreater risk for physical, mental, social and emotional difficultiesstemming from their condition. Mental health disorders such as anxietyand depression are common among people living with these conditions,partly due to the discrimination they can experience. Physicaldisability is also an issue for many people living with theseconditions. The emotional toll of living with a chronic illness can beimmense, leading to feelings of isolation, fear and frustration.
ThermoStem® couldpotentially help with this burden through its novel approach. Thenovelty of the ThermoStem® technology was acknowledged by the UnitedStates Patent Office’s TheNotice of Allowance was issued on February 24th of 2023. Byexpanding the ThermoStem® patent family with another issued patent,BioRestorative is positioned to further strengthen and secure itsnovel cell-based approach to treat obesity
Visit https://www.biorestorative.com for more information on the company and its product candidates.
This article wasoriginally published on Benzinga .
BioRestorativeTherapies was founded by scientists and researchers committed todeveloping stem cell therapies to address unmet needs in patients withhighly prevalent conditions.Our advances in stem cell biology anddelivery protocols harbor great promise in conditioning our bodies’own regenerative potential to treat major diseases more effectivelythan current interventions.Today, BioRestorative is activelydeveloping programs that aim to dramatically increase quality of carefor both (i) chronic back pain caused by disc degeneration, as well as(ii) metabolic disorders including obesity anddiabetes.
This post contains sponsored advertisingcontent. This content is for informational purposes only and is notintended to be investing advice.
ContactDetails
Investor Relations
CompanyWebsite
https://www.biorestorative.com/
Copyright (c) 2023 TheNewswire - All rights reserved.